ARTICLE | Top Story

UnitedHealth picks Harvoni

January 29, 2015 1:39 AM UTC

UnitedHealth Group Inc. (NYSE:UNH) said on Wednesday that it has selected Harvoni ledipasvir/ sofosbuvir from Gilead Sciences Inc. (NASDAQ:GILD) as its preferred regimen to treat HCV genotype 1 over Viekira Pak from AbbVie Inc. (NYSE:ABBV).

The decision will apply to the payer's 2015 formulary and will affect commercial, fully-insured customers in its Optum Rx pharmacy benefit manager, and self-insured customers, as well as its Medicare and Medicaid customers. ...